Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Metoject subcutaneous injection pen (methotrexate) pen – type autoinjector approved in Japan – Eisai

Written by | 24 Feb 2024

Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft für klinische Spezialpräparate mbH announced that they have obtained manufacturing and marketing approval from the… read more.

Obesity associated with more severe disease flares in early rheumatoid arthritis

Written by | 29 Nov 2023

Obesity is associated with worse flare symptoms and worse quality of life among patients with early rheumatoid arthritis, researchers reported on Nov. 12, 2023 at ACR Convergence 2023,… read more.

Study finds hydroxychloroquine lowers risk of nonalcoholic fatty liver disease in rheumatoid arthritis patients

Written by | 11 Nov 2023

New research at ACR Convergence 2023, the American College of Rheumatology’s (ACR) annual meeting, shows that treating rheumatoid arthritis with hydroxychloroquine (HCQ) reduced the risk of nonalcoholic fatty… read more.

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma

Written by | 2 Nov 2023

Galapagos NV and Alfasigma S.p.A. announced that they have signed a letter of intent contemplating a transfer of the Jyseleca business to Alfasigma, including the European and UK… read more.

Galapagos to review future of Jyseleca

Written by | 8 Aug 2023

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023… read more.

Managing anxiety and depression in arthritis

Written by | 5 Jun 2023

Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and… read more.

New breakthrough in the treatment of rheumatoid arthritis

Written by | 3 Feb 2023

A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones… read more.

Common workplace fumes and dusts may heighten rheumatoid arthritis risk

Written by | 9 Dec 2022

Breathing in common workplace dusts and fumes from agents such as vapours, gases, and solvents, may heighten the risk of developing rheumatoid arthritis, suggests research published online in… read more.

One in five patients with rheumatoid arthritis were undiagnosed during the pandemic

Written by | 6 Nov 2022

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests. The study, published today in The Lancet… read more.

Findings support repurposing rheumatoid arthritis drug auranofin for diabetes

Written by | 20 Oct 2022

Researchers at Baylor College of Medicine and collaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentially be repurposed to improve diabetes-associated symptoms. The study, which was… read more.

Key protein that drives rheumatoid arthritis damage

Written by | 28 Sep 2022

Scientists have identified a protein known as sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis. A chronic disease in which the immune system… read more.

FDA accepts for review supplemental application for Abrilada interchangeability – Pfizer

Written by | 5 Jun 2022

Pfizer Inc. announced that the FDA has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for Abrilada (adalimumab-afzb) as an interchangeable biosimilar… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.